Rameen Beroukhim
Rameen Beroukhim got his PhD at the University of Cambridge in 1996 and his MD at the University of California in 2000. He is currently a physician in the Department of Medical Oncology at the Dana-Farber Cancer Institute, an associate physician in medical oncology at Brigham and Women’s Hospital and an assistant professor of medicine at Harvard Medical School.
Hovedinnhold
Dr. Beroukhim co-chairs the International Cancer Genome Consortium effort to characterize structural alterations across 2800 cancer wholegenomes. He is also a principal investigator of three multi-investigator R01 grants, a U24 grant, and of individual and multi-PI foundation- and industry-funded grants. Dr. Beroukhim’s scientific focus is on the genomic features of oncogenesis and cancer progression in brain and other cancers, and the implications of these in identifying novel cancer dependencies, therapeutic strategies, and biomarkers.
The major focus of Dr. Beroukhim’s longstanding collaboration with CCBIO has been the genomic characterization of endometrial cancer. Since collaborating on the first integrated genomic characterization of endometrial cancers, identifying chromosomal alterations and RNA signatures that determine prognosis, the teams have since followed up with multiple publications including the first study describing the genomic evolution of large numbers of endometrial cancers through metastasis. The Beroukhim lab highly appreciate CCBIO’s collection of endometrial cancer tissue samples with deep clinical, radiologic, and molecular characterization, and hope to continue to leverage these resources for translational discovery. Current collaborations are focusing on generating more detailed descriptions of the endometrial cancer genome as it evolves through treatment and metastasis, integrating these data with radiologic and clinical data to build comprehensive radiogenomic profiles that inform how endometrial cancers develop and evolve, and using these data to interrogate novel treatment approaches in carefully selected endometrial cancer model systems.
